Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
47
INAB Quote, Financials, Valuation and Earnings
Last price:
$1.46
Seasonality move
:
-8.5%
Day range:
$1.20 - $1.58
52-week range:
$1.17 - $12.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.53x
Volume:
758.2K
Avg. volume:
435.4K
1-year change:
-79.23%
Market cap:
$7M
Revenue:
--
EPS (TTM):
-$4.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INAB
IN8bio, Inc.
|
-- | -$1.25 | -- | -69.8% | $46.90 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INAB
IN8bio, Inc.
|
$1.55 | $46.90 | $7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.43 | $0.85 | $684.2M | 9.12x | $0.80 | 0% | 10.55x |
|
NNVC
NanoViricides, Inc.
|
$1.25 | $6.50 | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $685.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INAB
IN8bio, Inc.
|
18.31% | 0.180 | 30.02% | 6.28x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INAB
IN8bio, Inc.
|
-$401K | -$4M | -119.8% | -158.01% | -- | -$3.5M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
IN8bio, Inc. vs. Competitors
-
Which has Higher Returns INAB or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to IN8bio, Inc.'s net margin of -255.85%. IN8bio, Inc.'s return on equity of -158.01% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital INABIN8bio, Inc.-- -$0.85 $16.1M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About INAB or NBY?
IN8bio, Inc. has a consensus price target of $46.90, signalling upside risk potential of 2925.81%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.35%. Given that IN8bio, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe IN8bio, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INABIN8bio, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is INAB or NBY More Risky?
IN8bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock INAB or NBY?
IN8bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. IN8bio, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INAB or NBY?
IN8bio, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. IN8bio, Inc.'s net income of -$3.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, IN8bio, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio, Inc. is -- versus 10.55x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INABIN8bio, Inc.-- -- -- -$3.9M NBYNovaBay Pharmaceuticals, Inc.10.55x 9.12x $521K -$1.3M
-
Which has Higher Returns INAB or NNVC?
NanoViricides, Inc. has a net margin of -- compared to IN8bio, Inc.'s net margin of --. IN8bio, Inc.'s return on equity of -158.01% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital INABIN8bio, Inc.-- -$0.85 $16.1M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About INAB or NNVC?
IN8bio, Inc. has a consensus price target of $46.90, signalling upside risk potential of 2925.81%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 420%. Given that IN8bio, Inc. has higher upside potential than NanoViricides, Inc., analysts believe IN8bio, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INABIN8bio, Inc.2 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is INAB or NNVC More Risky?
IN8bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock INAB or NNVC?
IN8bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INAB or NNVC?
IN8bio, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. IN8bio, Inc.'s net income of -$3.9M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, IN8bio, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INABIN8bio, Inc.-- -- -- -$3.9M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns INAB or OGEN?
Oragenics, Inc. has a net margin of -- compared to IN8bio, Inc.'s net margin of --. IN8bio, Inc.'s return on equity of -158.01% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital INABIN8bio, Inc.-- -$0.85 $16.1M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About INAB or OGEN?
IN8bio, Inc. has a consensus price target of $46.90, signalling upside risk potential of 2925.81%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.07%. Given that IN8bio, Inc. has higher upside potential than Oragenics, Inc., analysts believe IN8bio, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INABIN8bio, Inc.2 0 0 OGENOragenics, Inc.1 0 0 -
Is INAB or OGEN More Risky?
IN8bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock INAB or OGEN?
IN8bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INAB or OGEN?
IN8bio, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. IN8bio, Inc.'s net income of -$3.9M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, IN8bio, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INABIN8bio, Inc.-- -- -- -$3.9M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns INAB or PTN?
Palatin Technologies has a net margin of -- compared to IN8bio, Inc.'s net margin of --. IN8bio, Inc.'s return on equity of -158.01% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INABIN8bio, Inc.-- -$0.85 $16.1M PTNPalatin Technologies-- -- -- -
What do Analysts Say About INAB or PTN?
IN8bio, Inc. has a consensus price target of $46.90, signalling upside risk potential of 2925.81%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than IN8bio, Inc., analysts believe Palatin Technologies is more attractive than IN8bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INABIN8bio, Inc.2 0 0 PTNPalatin Technologies0 0 0 -
Is INAB or PTN More Risky?
IN8bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock INAB or PTN?
IN8bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INAB or PTN?
IN8bio, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. IN8bio, Inc.'s net income of -$3.9M is higher than Palatin Technologies's net income of --. Notably, IN8bio, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INABIN8bio, Inc.-- -- -- -$3.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns INAB or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to IN8bio, Inc.'s net margin of --. IN8bio, Inc.'s return on equity of -158.01% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital INABIN8bio, Inc.-- -$0.85 $16.1M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About INAB or TOVX?
IN8bio, Inc. has a consensus price target of $46.90, signalling upside risk potential of 2925.81%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3528.82%. Given that Theriva Biologics, Inc. has higher upside potential than IN8bio, Inc., analysts believe Theriva Biologics, Inc. is more attractive than IN8bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INABIN8bio, Inc.2 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is INAB or TOVX More Risky?
IN8bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock INAB or TOVX?
IN8bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IN8bio, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INAB or TOVX?
IN8bio, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. IN8bio, Inc.'s net income of -$3.9M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, IN8bio, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IN8bio, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INABIN8bio, Inc.-- -- -- -$3.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.16% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 1.47% over the past day.
Buy
69
QBTS alert for Dec 23
D-Wave Quantum, Inc. [QBTS] is down 6.65% over the past day.
